LP(A) LEVELS IN DIFFERENT TYPES OF DYSLIPIDEMIA IN THE FRENCH POPULATION

被引:34
作者
BOYER, H
DEGENNES, JL
TRUFFERT, J
CHATELLIER, G
DAIROU, F
BRUCKERT, E
机构
[1] HOP LA PITIE SALPETRIERE,SERV ENDOCRINOL,83 BD HOP,F-75651 PARIS 13,FRANCE
[2] HOP LA PITIE SALPETRIERE,SERV INFORMAT MED,PARIS,FRANCE
关键词
Atherosclerosis; Hyperlipidemia; Lipoprotein (a);
D O I
10.1016/0021-9150(90)90183-J
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The serum lipoprotein Lp(a) concentration was measured in 1065 individuals in order to assess whether there was a relation between the type of dyslipidemia and the level of Lp(a). Males and females, aged between 2 and 83 years old, were included in the study. Quantification was performed by an immunonephelometric technique. The whole population was divided into normolipidemic (NL), type IIa without xanthoma (type IIa), type IIa with xanthoma (FH), type IIb and type IV phenotypes. Lp(a) level was arbitrarily divided into 5 subclasses in each group of dyslipidemia and in the normolipidemic group. In addition each group was divided according to sex and whether or not they were under treatment. We observed a significant difference between the median Lp(a) level of the normolipidemic group (NL) and of the dyslipidemic group as a whole. Median Lp(a) levels in the 4 dyslipidemic groups did not differ significantly. Sex, age and treatment did not influence the distribution of Lp(a) values distribution. Only weak correlations (Spearman's rank test) were observed between Lp(a) and other lipid parameters (total cholesterol, LDL, apo B, HDL, triglycerides): the highest correlation coefficient (r′= 0.15) was between Lp(a) and apo B. We conclude that Lp(a) level is not influenced by the type of dyslipidemia, sex or hypolipidemic drugs. © 1990.
引用
收藏
页码:61 / 69
页数:9
相关论文
共 28 条
[1]   IMMUNOCHEMICAL QUANTIFICATION OF HUMAN PLASMA LP(A) LIPOPROTEIN [J].
ALBERS, JJ ;
HAZZARD, WR .
LIPIDS, 1974, 9 (01) :15-26
[2]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[3]  
ARMSTRONG VW, 1985, J LIPID RES, V26, P1314
[4]  
BEAUMONT JL, 1970, B WORLD HEALTH ORGAN, V43, P891
[5]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[6]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[7]   GENETICS OF THE QUANTITATIVE LP(A) LIPOPROTEIN TRAIT .3. CONTRIBUTION OF LP(A) GLYCOPROTEIN PHENOTYPES TO NORMAL LIPID VARIATION [J].
BOERWINKLE, E ;
MENZEL, HJ ;
KRAFT, HG ;
UTERMANN, G .
HUMAN GENETICS, 1989, 82 (01) :73-78
[8]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[9]  
BUCOLO G, 1973, CLIN CHEM, V19, P476
[10]  
BURN J, 1987, RECENT ADV CARDIOLOG, V10, P27